Key Points
- COO Alistair Milnes sold 6,660 shares (3,244 on Jan 2 at $6.80 and 3,416 on Jan 5 at $6.46), trimming his stake by about 2.3% and leaving him with roughly 140,133 shares valued near $953,000.
- Multiple senior executives also sold shares the same week — CEO Kevin Lee (21,314 shares), CFO Alethia Young (7,623 shares) and CAO Travis Thompson (2,432 shares) — indicating notable insider selling across leadership.
- Bicycle Therapeutics trades around $6.57 with a market cap of about $456 million, reported negative EPS and margins last quarter, and carries an average analyst rating of "Hold" despite an average target price near $19.73.
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC - Get Free Report) COO Alistair Milnes sold 3,244 shares of the firm's stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $6.80, for a total value of $22,059.20. Following the sale, the chief operating officer directly owned 140,133 shares of the company's stock, valued at $952,904.40. This trade represents a 2.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Alistair Milnes also recently made the following trade(s):
- On Monday, January 5th, Alistair Milnes sold 3,416 shares of Bicycle Therapeutics stock. The stock was sold at an average price of $6.46, for a total value of $22,067.36.
Bicycle Therapeutics Stock Performance
Shares of BCYC opened at $6.57 on Wednesday. The firm has a market cap of $455.76 million, a PE ratio of -1.81 and a beta of 1.52. Bicycle Therapeutics PLC Sponsored ADR has a twelve month low of $6.03 and a twelve month high of $15.47. The firm's 50 day moving average price is $6.97 and its 200 day moving average price is $7.42.
Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last released its quarterly earnings results on Thursday, October 30th. The company reported ($0.85) earnings per share for the quarter, beating analysts' consensus estimates of ($1.09) by $0.24. The business had revenue of $11.73 million for the quarter, compared to the consensus estimate of $8.25 million. Bicycle Therapeutics had a negative net margin of 884.51% and a negative return on equity of 36.05%. On average, sell-side analysts anticipate that Bicycle Therapeutics PLC Sponsored ADR will post -3.06 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
A number of research firms have recently commented on BCYC. Citizens Jmp lifted their price target on shares of Bicycle Therapeutics from $10.00 to $12.00 and gave the company a "market outperform" rating in a research report on Friday, October 31st. Truist Financial initiated coverage on Bicycle Therapeutics in a research report on Monday, November 24th. They issued a "hold" rating and a $10.00 price target on the stock. Weiss Ratings restated a "sell (e+)" rating on shares of Bicycle Therapeutics in a research note on Monday, December 22nd. Royal Bank Of Canada reissued a "sector perform" rating and issued a $11.00 price objective (down from $27.00) on shares of Bicycle Therapeutics in a research report on Friday, October 31st. Finally, JMP Securities set a $12.00 price objective on shares of Bicycle Therapeutics in a research note on Friday, October 31st. Seven investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $19.73.
Read Our Latest Stock Report on BCYC
Institutional Trading of Bicycle Therapeutics
Institutional investors have recently modified their holdings of the company. Millennium Management LLC raised its stake in shares of Bicycle Therapeutics by 156.5% in the first quarter. Millennium Management LLC now owns 453,428 shares of the company's stock valued at $3,850,000 after purchasing an additional 276,671 shares in the last quarter. Goldman Sachs Group Inc. acquired a new stake in Bicycle Therapeutics during the first quarter worth $214,000. Woodline Partners LP bought a new stake in Bicycle Therapeutics in the 1st quarter valued at $3,088,000. Acadian Asset Management LLC acquired a new position in shares of Bicycle Therapeutics in the 1st quarter valued at $1,065,000. Finally, Janney Montgomery Scott LLC bought a new position in shares of Bicycle Therapeutics during the 2nd quarter worth about $697,000. Institutional investors and hedge funds own 86.15% of the company's stock.
Key Stories Impacting Bicycle Therapeutics
Here are the key news stories impacting Bicycle Therapeutics this week:
- Negative Sentiment: CEO Kevin Lee sold a total of 21,314 shares across trades on Jan. 2 and Jan. 5 (average prices ~$6.80 and ~$6.46), reducing his stake by roughly 1.6–1.7%; he still holds ~619k shares. SEC Form 4 — Kevin Lee
- Negative Sentiment: CFO Alethia Young sold 7,623 shares across Jan. 2 and Jan. 5 trades (avg prices ~$6.80 and ~$6.49), cutting her position by ~3.5–4.7%; she retains ~87k shares. SEC Form 4 — Alethia Young
- Negative Sentiment: COO Alistair Milnes sold 6,660 shares across the two dates (avg prices ~$6.80 and ~$6.46), a ~2.3–2.4% reduction; he still holds ~137k–140k shares. SEC Form 4 — Alistair Milnes
- Negative Sentiment: CAO Travis Alvin Thompson sold 2,432 shares across Jan. 2 and Jan. 5 (avg prices ~$6.80 and ~$6.45), trimming his stake by ~1.6–1.9%; he remains a meaningful holder. SEC Form 4 — Travis Alvin Thompson
About Bicycle Therapeutics
(
Get Free Report)
Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company's core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.
Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
